EpiAxis Therapeutics, A Leader in Novel Cancer Therapy, Announces the Appointment of Three New Non-Executive Directors
EpiAxis Therapeutics is a pioneering Australian pharma company that is advancing its epigenetic assets to target LSD1 as a treatment for metastatic cancer. SYDNEY, AUSTRALIA, July 27, 2020 /EINPresswire.com/ -- Following recent advances in its …